LSD1-IN-27

LSD1-IN-27 is an orally active LSD1 inhibitor (IC50: 13 nM) . LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer[1].

Product Specifications

CAS Number

[2904571-94-2]

UNSPSC

12352005

Target

Histone Demethylase; PD-1/PD-L1

Type

Reference compound

Related Pathways

Epigenetics; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lsd1-in-27.html

Purity

98.88

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC1=CC=C2C(C(NC3=CC=C(N(C)C)C=C3)=C4C(C(C)=C(C)C=C4)=N2)=C1

Molecular Formula

C24H25N3

Molecular Weight

355.48

References & Citations

[1]Dai XJ, et al. Novel acridine-based LSD1 inhibitors enhance immune response in gastric cancer. Eur J Med Chem. 2023 Nov 5;259:115684.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, protect from light)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

FAB2018RW 0.1 mL

Mouse Monoclonal SOX2 Antibody (245610R) [DyLight 650]

Ask

View Details

DF15502-BP 1 mg

CTC1 Peptide

Ask

View Details

NBP2-09174 0.1 mg

RPS14 Overexpression Lysate (Native) - (Dry Ice)

Ask

View Details

APR31004G-01 50 µL

SLC23A1 Antibody (N-term) [APR31004G]

Ask

View Details

APR31004G-02 100 µL

SLC23A1 Antibody (N-term) [APR31004G]

Ask

View Details

APR31004G-03 200 µL

SLC23A1 Antibody (N-term) [APR31004G]

Ask

View Details